My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format

Send to:

Choose Destination

    Magy Onkol. 2009 Mar;53(1):81-2.

    [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the health insurance reimbursement for Emend(aprepitant)]

    [Article in Hungarian]

    Pikó B; Hungarian College of Oncology and Radiotherapy, Section of Financing.

    Budapest.

    PMID: 19318331 [PubMed - indexed for MEDLINE]

    Publication Types, MeSH Terms, Substances

    Publication Types:

    MeSH Terms:

    Substances:

    LinkOut - more resources

    Full Text Sources:

    Medical:

    Libraries:

    Supplemental Content

    Click here to read Click here to read

    Related articles

    Patient drug information

    • Aprepitant (Emend®)

      Aprepitant is used with other medications to prevent nausea and vomiting caused by cancer chemotherapy treatment. Aprepitant is also used alone to prevent nausea and vomiting caused by surgery. Aprepitant is not used to ...

    • Source: AHFS Consumer Medication Information

    All links from this record

    • Compound (MeSH Keyword)

      PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

    • Substance (MeSH Keyword)

      PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

    • Related Articles

      Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.

    Recent activity